COMPARISON
Abaloparatide vs Angiotensin II
6 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Abaloparatide is authorised or registered in 5 and Angiotensin II in 3 of the 10 registers read. Abaloparatide: No trial states a phase. Angiotensin II: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Abaloparatide | Angiotensin II | |
|---|---|---|
| Registered trials differs | 25 clinicaltrials.gov · 2026-10-03 | 364 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Tymlos openfda · 2026-10-03T17:23:44.062Z | FDA-approved: ANGIOTENSIN II openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2022-12-12 ema · 2026-10-03 | 2019-08-23 ema · 2026-10-03 |
| EU refused on differs | 2018-04-03 ema · 2026-10-03 | Not checked no record of "refusedOn" for angiotensin-ii |
| ATC code differs | H05AA04 ema · 2026-10-03 | C09 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Abaloparatide | placebo | Angiotensin II | placebo |
|---|---|---|---|---|
| Hypertension | 6.2% | 6.0% | 5.5% | 5.7% |
| Hypercalciuria | 9.7% | 8.9% | - | - |
| Dizziness | 9.4% | 5.5% | - | - |
| Nasopharyngitis | 8.8% | 8.5% | - | - |
| Arthralgia | 8.3% | 9.3% | - | - |
| Nausea | 8.0% | 3.1% | - | - |
| Headache | 7.2% | 6.1% | - | - |
| Back pain | 7.1% | 8.2% | - | - |
| Upper respiratory tract infection | 6.9% | 7.8% | - | - |
| Influenza | 5.8% | 4.5% | - | - |
| Multi-organ failure | - | - | 15.3% | 14.6% |
| Septic shock | - | - | 11.0% | 6.3% |
| Atrial fibrillation | - | - | 10.4% | 10.1% |
| Thrombocytopenia | - | - | 9.2% | 6.3% |
| Hypokalaemia | - | - | 8.0% | 6.3% |
| Hypotension | - | - | 8.0% | 4.4% |
| Anaemia | - | - | 6.7% | 5.7% |
| Delirium | - | - | 5.5% | 0.6% |
| Pleural effusion | - | - | 4.9% | 5.1% |
Trial register Abaloparatide: 4 placebo-controlled trials; Angiotensin II: 1. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Abaloparatide side effects · Angiotensin II side effects
LEGAL STATUS
Approval in each country read
| Country | Abaloparatide | Angiotensin II | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Not on the register | Not on the register | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Not on the register | Regulator Swissmedic |
| Brazil | Not on the register | Not on the register | Regulator ANVISA |
| Serbia | Not on the register | Not on the register | Regulator ALIMS |
| Singapore | Not on the register | Not on the register | Regulator HSA |
| Turkey | Not on the register | Not on the register | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.